Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

BACKGROUND: Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured in the ATTRACTION-2 trial, we used patients with prior trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Taroh, Kang, Yoon-Koo, Chao, Yee, Ryu, Min-Hee, Kato, Ken, Cheol Chung, Hyun, Chen, Jen-Shi, Muro, Kei, Ki Kang, Won, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Tanimoto, Mitsunobu, Chen, Li-Tzong, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942596/
https://www.ncbi.nlm.nih.gov/pubmed/31087200
http://dx.doi.org/10.1007/s10120-019-00970-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942596/
https://www.ncbi.nlm.nih.gov/pubmed/31087200
http://dx.doi.org/10.1007/s10120-019-00970-8

Ejemplares similares